Shepherd, J., Jones, J. (Jeremy), Dr., Hartwell, D. (Debbie L.), Davidson, Peter, Price, A. (Alison) and Waugh, Norman. (2007) Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation. Health Technology Assessment, Vol.11 (No.11). ISSN 1366-5278

Preview	Text WRAP_Waugh_monmildhepC.pdf - Published Version Download (850Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh5_Coversheet_FinalVersion.pdf Download (168Kb) | Preview

Abstract

Objectives: To assess the clinical effectiveness and cost-effectiveness of pegylated interferon alfa (PEG) and non-pegylated interferon alfa (IFN) and ribavirin (RBV) for the treatment of adults with histologically mild chronic hepatitis C (HCV) infection. Data sources: Electronic bibliographic databases were searched up to July 2005. Review methods: A systematic review and an economic evaluation were carried out. A Markov state transition model was developed to estimate the cost-effectiveness of treatment strategies for adults with mild chronic HCV. Results: Among the included studies, eight randomised controlled trials (RCTs) of antiviral treatment in mild HCV were identified and included. In general these RCTs were of good quality. The results suggested that effectiveness, particularly with respect to sustained virological response was similar in patients with mild disease to the results obtained in patients with moderate/severe disease. This finding was supported by RCTs reporting the results for mild HCV sub-groups. The authors’ cost-effectiveness analysis showed that early treatment compared with watchful waiting is associated with quality-adjusted life-year (QALY) gains but with increased treatment costs. The base-case incremental costs per QALY for 48 weeks of treatment are: watchful waiting with IFN + RBV versus best supportive care = £3097–6585; early treatment with IFN + RBV versus watchful waiting with IFN + RBV = £5043–8092; watchful waiting with PEG 2a + RBV versus best supportive care = £3052; early treatment with PEG 2a + RBV versus watchful waiting with PEG 2a + RBV = £5900; watchful waiting with PEG 2b + RBV versus best supportive care = £2534; and early treatment with PEG 2b + RBV versus watchful waiting with PEG 2b + RBV = £5774.These results were consistent with previous assessments of cost-effectiveness. Conclusion: This systematic review and economic evaluation show that patients with histologically mild HCV can be successfully treated with both pegylated and non-pegylated interferon alfa. Early treatment and watchful waiting strategies are associated with acceptable cost-per-QALY estimates. Research needs to be directed towards newer, potentially more effective interventions, particularly those that improve treatment response in patients with genotype 1, with minimal adverse effects. Further research is required into the natural history of HCV to estimate better the rate of liver disease progression, and also into the effectiveness of non-invasive biochemical markers of liver disease, as an alternative to liver biopsy.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Hepatitis C -- Treatment, Ribavirin -- Effectiveness, Interferon -- Effectiveness
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	April 2007
Volume:	Vol.11
Number:	No.11
Number of Pages:	224
Identification Number:	10.3310/hta11110
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707–13. 2. Balogun MA, Ramsay ME, Parry JV, Donovan L, Andrews NJ, Newham JA, et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sex Transm Infect 2003;79:301–6. 3. Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002;51:601–8. 4. Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999;58:127–31. 5. Booth JC, O’Grady J, Neuberger J, Royal College of Physicians of London, British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49 Suppl 1:i1–i21. 6. Dillon JF. Hepatitis C: What is the best treatment? J Viral Hepat 2004;11 Suppl 1:23–7. 7. Royal College of Physicians/British Association for the Study of the Liver. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C – part review of existing guidance no. 75. Submission to NICE on behalf of the Royal College of Physicians/British Association for the Study of the Liver. 2005. 8. The Hepatitis C Trust. Submission to NICE for the partial review of existing guidance no. 75, assessing the use of interferon alpha and ribavirin in the treatment of mild chronic hepatitis C. 2005. 9. The Haemophilia Society. Submission to NICE for the appraisal of hepatitis C (mild to moderate) – pegylated interferons, ribavirin and alpha interferon. 2005. 10. Shepherd J, Brodin HFT, Cave CB, Waugh NR, Price A, Gabbay J. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005;21:47–54. 11. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon a-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8(39). 12. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost-effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332–8. 13. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239–44. 14. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57. 15. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005;25:52–64. 16. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36 (5 Suppl 1): S152–60. 17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65. 18. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426–32. 19. Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 2004;57:402–6. 20. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005;41:82–7. 21. Desmet VJ. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431–435][comment]. Journal of Hepatology 2003;38:382–6. 22. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5. 23. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9. 24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93. 25. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;1:15–20. 26. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574–9. 27. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344–55. 28. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704–13. 29. Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002;45:219–26. 30. Department of Health. Hepatitis C action plan for England. London: Department of Health; 2004. 31. Health Protection Agency. Shooting up – infections among injecting drug users in the United Kingdom 2003, an update: October 2004. London: Health Protection Agency; 2004. 32. Harris HE, Ramsay ME, Heptonstall J, Soldan K, Eldridge KP. The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. J Viral Hepat 2000;7:420–7. 33. Price D, Schmid M, Agarwal K, Hewett M, Craig W, Burt A, et al. Chronic hepatitis C in injecting drugs users: a comparison with non-injecting drugs users in the same geographic area. To be published. 34. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC, Trent Hepatitis CSG. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451–5. 35. Collier JD, Woodall T, Wight DG, Shore S, Gimson AE, Alexander GJ. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 2005;12:74–80. 36. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–9. 37. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257–65. 38. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004;36:646–54. 39. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562–9). 40. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035–40. 41. Bayliss MS. Methods in outcomes research in hepatology: definitions and domains of quality of life. Hepatology 1999;29 (6 Suppl):3S–6S. 42. Conry CC, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691–6. 43. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9:295–303. 44. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433–9. 45. Forton DM, Taylor-Robinson SD, Thomas HC. Reduced quality of life in hepatitis C – is it all in the head? J Hepatol 2002;36:435–8. 46. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre; 1993. 47. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409–17. 48. Bonkovsky HL, Woolley JM. Reduction of healthrelated quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999;29:264–70. 49. Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, et al. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004;40:1434–41. 50. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–12. 51. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482–6. 52. Ware JE, Bayliss MS, Mannocchia M, Davis GL, Bassaris H, Batey R, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999;30: 550–5. 53. National Plan for Liver Services UK: specialised services for hepatology and hepato-pancreato-biliary (HPB) surgery. London: British Liver Trust, British Association for the Study of the Liver, British Society for Gastroenterology; 2004. 54. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4(33). 55. Cramp ME, Rosenberg W. Guidance on the treatment of hepatitis C incorporating the use of pegylated interferons. URL: http://www bsg org uk/pdf_word_docs/pegylated_2003 doc. Accessed 17 June 2005. 56. Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001;7:339–45. 57. Irving WL, Smith S, Cater R, Pugh S, Neal K, Coupland C et al. Clinical pathways for patients with newly diagnosed hepatitis C – what actually happens. J Viral Hepat 2006;13:264–71. 58. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002;36(5 I):S1–2. 59. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. [Published erratum appears in Hepatology 2004;40:269.] Hepatology 2004;39:1147–71. 60. Schaefer M, Heinz A, Backmund M, Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 2004; 99:1167–75. 61. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005;42:266–74. 62. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD Report Number 4. 2nd ed. York, York Publishing Services; York: 2001. 63. Mangia A, Villani MR, Minerva N, Leandro G, Bacca D, Cela M, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol 2001; 34:441–6. 64. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC, Swedish HCV Treatment Group. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol 2002;14:627–33. 65. Wright M, Forton D, Main J, Goldin R, Torok E, Tedder R, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005;12:58–66. 66. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724–32. 67. Cheng PN, Chow NH, Hu SC, Young KC, Chen CY, Jen CM, et al. Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Dig Liver Dis 2002;34:851–6. 68. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451–9. 69. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55. 70. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, doubleblind, placebo-controlled trial of interferon alpha- 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351: 83–7. 71. O’Brien C, Wintfeld N, Patel KK, Zeuzem S, Shiffman ML, Diago M, et al. The impact of sustained virological response (SVR) on healthrelated quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2a (PEGASYS(R)) and ribavirin (COPEGUS(R)). J Hepatol 2004;40 (Suppl. 1):147. 72. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433–8. 73. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403. 74. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303–13. 75. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131–7. 76. Schering-Plough Ltd. ViraferonPeg in combination with ribavirin in the treatment of mild chronic hepatitis C in England and Wales – a submission to the National Institute for Health and Clinical Excellence. Welwyn Garden City, Herts: Schering-Plough Ltd; 2005. 77. August-Jorg BS, Borovicka J, Dufour JF, Gonvers JJ, Henz S, Hermann R, et al. Twentyfour vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly 2003;133:455–60. 78. Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000;20:427–36. 79. Hytiroglou P, Thung SN, Gerber MA. Histological classification and quantitation of the severity of chronic hepatitis: keep it simple! Semin Liver Dis 1995;15:414–21. 80. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20. 81. de Ledinghen V, Trimoulet P, Winnock M, Bernard PH, Bourliere M, Portal I, et al. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002;36:819–26. 82. de Ledinghen V, Trimoulet P, Winnock M, Foucher J, Bourliere M, Desmorat H, et al. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol 2002;36:672–80. 83. Getachew Y, Browning JD, Prebis M, Rogers T, Brown GR. Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation. Aliment Pharmacol Ther 2004; 20:629–36. 84. Mangia A, Santoro R, Piattelli M, Leandro G, Minerva N, Annese M, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol 2002;37:109–16. 85. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J, Poynard T, et al. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. [Published erratum appears in Hepatology 2000;32:446]. Hepatology 2000;31:211–18. 86. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–92. 87. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4(33). 88. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the costeffectiveness of a single course of interferonalpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855–65. 89. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651–8. 90. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepat 1998;5:313–21. 91. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228–37. 92. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A costeffectiveness analysis. Ann Intern Med 2000;133: 665–75. 93. Grieve R, Roberts J. Economic evaluation for hepatitis C. Acta Gastroenterol Belg 2002;65:104–9. 94. Stein K, Rosenberg W, Wong J, Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253–8. 95. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant alphainterferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J Hepatol 1990;11 (Suppl 1):S31–5. 96. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996;24:1034–40. 97. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11 (Suppl 1):S43–9. 98. Metreau JM. Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the study of NANB/C chronic hepatitis treatment. Gut 1993;34 (2 Suppl):S112–13. 99. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the longterm treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457–62. 100. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995;23:487–96. 101. Barbaro G, Di LG, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, et al. Evaluation of longterm efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin–Interferon in Chronic Hepatitis Italian Group Investigators. J Hepatol 2000;33:448–55. 102. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240–3. 103. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273–81. 104. Mattsson L, Weiland O, Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver 1988;8:184–8. 105. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825–32. 106. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378–86. 107. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993;34 (2 Suppl):S13–16. 108. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517–24. 109. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156:761–73. 110. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995;22:1863–73. 111. Chong CAKY, Gulamhussein A, Jenny HE, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630–8. 112. Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004;164:2371–82. 113. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bezjak A, Trachtenberg J, et al. Construction of the Patient- Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol 2000;53:920–30. 114. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39–55. 115. Pojoga C, Dumitrascu DL, Pascu O, Grigorescu M, Radu C, Damian D. Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy. Eur J Gastroenterol Hepatol 2004;16:27–31. 116. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001;96:2199–205. 117. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088–93. 118. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics. Discussion Paper 138. York: Centre for Health Economics, University of York; 1995. 119. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–72. 120. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511–17. 121. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8(39). 122. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372–4. 123. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004;41:474–81. 124. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33:704–7. 125. National Institute for Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. URL: http://www.nice.org.uk/page.aspx?o=82254. 2004. 126. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425–32. 127. Roche UK. Pegasys (peginterferon alfa-2a) NICE Submission – achieving clinical excellence in the treatment of mild chronic Hepatitis C. Welwyn Garden City, Herts: Roche UK; 2005. 128. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M, et al. Assessing healthrelated quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002;8:263–70. 129. Longworth L, Young T, Ratcliffe J, Bryan S, Buxton M. Economic evaluation of the Transplantation Programme in England and Wales: an assessment of the costs of liver transplantation. Report to the Department of Health. 2001. 130. Curtis L, Netten A. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2004. 131. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36 (5 Suppl 1):S145–51. 132. Hopwood M, Southgate E. Living with hepatitis C: a sociological review. Crit Public Health 2003; 13:251–67. 133. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438–50. 134. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352: 2609–17. 135. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250–7. 136. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000;95: 1524–30.
URI:	http://wrap.warwick.ac.uk/id/eprint/45928

Request changes to a record

Actions (login required)

View Item